Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 33Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16cemiplimab 15atezolizumab 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Sonazoid × 1 year × Clear all
NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

The Netherlands Cancer Institute

Phase 2/3 Recruiting
91 enrolled
BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡